ProQR Therapeutics NV (PRQR)

6.38
+0.15(+2.41%)
After Hours
6.38
0.00(0.00%)
- Real-time Data
  • Volume:
    713,234
  • Bid/Ask:
    6.38/6.45
  • Day's Range:
    6.05 - 6.53

PRQR Overview

Prev. Close
6.23
Day's Range
6.05 - 6.53
Revenue
11.42M
Open
6.18
52 wk Range
3.4 - 9.44
EPS
-1.13
Volume
713,234
Market Cap
421.9M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
3,571,663
P/E Ratio
-
Beta
0.51
1-Year Change
21.92%
Shares Outstanding
66,127,887
Next Earnings Date
Aug 04, 2021
What is your sentiment on ProQR Therapeutics NV?
or
Market is currently closed. Voting is open during market hours.

ProQR Therapeutics NV News

ProQR Therapeutics NV Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyStrong BuyBuy
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyBuy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyBuy

ProQR Therapeutics NV Company Profile

ProQR Therapeutics NV Company Profile

Employees
150

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Read More
  • Guy let buy more nakd
    0
    • Rip who bought at 9 typical pump and dump
      4
      • Sell now pump amd dump
        4
        • 11 today
          0
          • Nope
            0
          • Nice tricking people dude
            0
        • amazing rise.
          0
          • target price up from 19 to 35 listed as a hold for now
            0
            • https://finance.yahoo.com/news/2-strong-buy-penny-stocks-153448116.html Strong Buy rating & analysts prediction $20
              0
              • Good moment for buy more
                0
                • ProQR, my best investment and they have just started! Go Dutchy Pharma!
                  0
                  • $PRQR Phase 1b top-line data due September 25, 2017 for Cystic Fibrosis
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.